Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

This phase 3 randomised trial asked whether sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, improves survival over physician's choice chemotherapy (doxorubicin or paclitaxel) in women with advanced or recurrent endometrial cancer previously treated with platinum chemotherapy and immunotherapy. In 776 patients, sac-TMT significantly prolonged progression-free survival (median 7.2 vs 3.9 months; HR 0.59) and overall survival (median 19.0 vs 12.1 months; HR 0.68), at the cost of more grade 3 or higher adverse events (69% vs 57%). The authors conclude that sac-TMT should be considered a new standard of care for this patient population with few effective options.